The Royal Free Hospital participates in a study on an app for liver disease
An app that allows doctors to remotely monitor patients with liver disease can lead to reduced hospitalizations, according to a new study from the UK’s Royal Free Hospital.
Funded by INNOVATE UK, the trial involved patients taking daily blood pressure, weight and ECG measurements using hardware technology. They were also asked to do a modified “stroop test” to measure their brain function.
The data was then transmitted to the app and displayed via a secure server and digital platform, to help liver specialists identify any deterioration in patient health.
Clinicians were then able to step in with advice on adjusting medications and helping cirrhosis patients avoid unnecessary hospitalizations.
WHY IS IT IMPORTANT
Patients with end-stage liver disease may experience deterioration in their health, which can often lead to multiple organ failure and acute hospitalization.
This can lead to hospitalization and discharge and require intensive care treatment, including assistance with ventilation and their kidneys.
Through the small study of 20 patients, the team at Royal Free Hospital found that patients using the CirrhoCare app were less likely to need hospitalization than those who did not.
If they were to be admitted, patients using the app were likely to be discharged earlier and needed fewer outpatient procedures.
Grant applications from other NHS funding sources are sought to facilitate a larger controlled trial and further development of the technology.
THE BROADER CONTEXT
111, a Chinese health care platform, listed on Nasdaq, entered into a strategic cooperation agreement with Jiangsu-based drug research and development company Suzhou Zelgen Biopharmaceuticals Co., to create a platform virtual for patients with liver cancer.
ON THE RECORD
Professor Mookerjee said: “The participants said it was easy to follow directions, allowed them to focus and understand their condition better, and it helped them feel more in control.
“These are very sick patients for whom the average mortality can reach half in six to 12 months. For us, this was very helpful as we could find out if, for example, a person had a brain dysfunction or fluid buildup, and organize changes in their treatment in the community or, if necessary, the bring to the hospital to help him. “